Related references
Note: Only part of the references are listed.tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)
C. J. Poole et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[ plus ] operable breast cancer
Antonio Llombart-Cussac et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
E. J. Macaskill et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Sirwan Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients
Xiangnan Kong et al.
EUROPEAN JOURNAL OF CANCER (2011)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Clinically Node-Negative Patients After Neoadjuvant Chemotherapy for Breast Cancer-A Systematic Review and Meta-Analysis
Veronique K. M. Tan et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results
Banu K. Arun et al.
ONCOLOGIST (2011)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer
Jae Hong Seo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy - Implications for a pathologist
Tanuja Shet et al.
BREAST JOURNAL (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer
Pedro F. Escobar et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
DJ Manton et al.
BRITISH JOURNAL OF CANCER (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer
GB Mann et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0)
SVS Deo et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
JY Pierga et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
